Latest Commercialisation News

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Everest Metals Corporation, in partnership with Edith Cowan University, has won a $490,500 grant to accelerate its innovative rubidium extraction technology at the Mt Edon project, positioning Australia to establish its first sovereign rubidium supply.

Elevate Uranium Ltd has completed a $25 million capital raising and is nearing steady state operations of its U-pgrade pilot plant in Namibia, while expanding its uranium resource portfolio through extensive drilling and a strategic acquisition from Core Lithium Ltd.

Nanoveu Limited has raised A$7.5 million through a strategic placement to accelerate the commercial rollout of its cutting-edge EMASS ECS-DoT semiconductor technology, including a rapid 16nm chip tape-out and live drone validation.

Blue Star Helium has achieved its first helium production at the Galactica Project, marking a key milestone as it optimizes plant operations and prepares for commercial ramp-up.

Neurizon Therapeutics has secured trademark protection for its NEURIZON® brand across major pharmaceutical markets, reinforcing its intellectual property strategy as it advances its lead drug candidate NUZ-001.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

VRX Silica Limited has locked in six binding offtake contracts totaling nearly 1 million tonnes per annum and appointed a new CEO, marking significant progress for its Arrowsmith North silica sand project.

Cambium Bio has locked in a A$2.4 million strategic investment from Zheng Yang Biomedical Technology, reinforcing its push into pivotal Phase 3 trials for its dry eye disease treatment.

Hiremii Group has raised $1.764 million through a strategic placement to fuel growth of its AI-driven recruitment platform and appointed Vaughan Webber as its new Chair.

4DMedical Limited has raised AU$150 million to accelerate the commercial rollout of its FDA-cleared CT, VQ lung imaging technology in the US, leveraging a strategic partnership with Philips. This funding aims to expand adoption across major medical centres and government healthcare programs.

Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.